Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.

ABSTRACT:

Introduction

Respiratory syncytial virus (RSV) causes great morbidity and mortality among newborns. Nirsevimab represents a prophylactic alternative used in Spain for a universal prophylaxis strategy of all infants. The aim of this study was to estimate the economically justifiable price (EJP) of nirsevimab in Spain, being the price to consider nirsevimab efficient compared with the standard of practice (administration of palivizumab in eligible infants and no intervention in all other).

Methods

An economic model based on a decision tree was developed to conduct a cost-utility analysis. The RSV epidemiology, RSV-related health events, clinical variables, resources consumption, costs and utilities were derived from the scientific literature and agreed by a multidisciplinary a

SUBMITTER: Gil-Prieto R 

PROVIDER: S-EPMC12315020 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature